Institute for International Research

In our eight years of running the Phase I Clinical Trials conference, IIR's research team has uncovered many pertinent issues of which we have provided solutions through cutting edge presentations, case studies, interactive panels and other forms of shared learning. This year in speaking with Phase I Clinical Professionals, we uncovered an interesting development so many of you share – the need to get to proof of concept much faster.  We see how this impacts the design of Phase I trials, how patients are being brought in earlier as opposed to healthy volunteers and the push to test not just for safety but also efficacy.

Providing Solutions to the Challenge of Getting to Proof of Concept Faster
IIR's eighth annual Phase I conference presents more than 25 sessions with break out tracks, workshops and interactive panels that address all steps involved with the challenge of getting to proof of concept faster and more including:

• Biomarker Validation versus Biological Effects – Is your Drug Really having an Effect?
• Strategic Planning for Patient Recruitment in Phase I: Healthy Volunteers versus Disease Populations
• The Challenge – Getting to Proof of Concept Faster
  • Part I: A Paradigm Shift in the Works – Translational Medicine and Pharmacogenomix in Phase I Clinical Trials
  • Part II: How can Working with Patients Earlier in Phase I will get you to Proof of Concept Faster?
  • Part III: How to Choose the Most Viable Candidate to Invest In? Optimizing Economics
• Therapeutics Roundtable
• IRB Regulations
• Current Technologies that are Helping Phase I Candidates Get to Proof of Concept
• Optimizing your Outsourcing Relationships

Plus, Specialized Break Out Sessions On:

• Preclinical Data and Using it to Maximize Phase I Studies
• Innovative Trial Design and Management
• QT Studies – Is This the Only Effective Method to Measure Cardiac Safety?
• Phase I Trials Abroad
• Outsourcing, Site Management & Safety
  

Conference Goal
Our goal is for you to be equipped to develop a strategy to establish proof of concept faster, while still ensuring patient safety. Bringing together leading innovators from pharmaceutical and biotechnology companies, as well as academia, CROs, sites and patient recruitment companies – this is the conference that will allow you to learn from thought leaders from the industry. From their experience and examples, you will gain insight to form an action plan that will increase efficacy, reduce cost and improve safety of your Phase I trials.

Please take the time to review the agenda for 2007. We are proud to present the best content that will provide you with new paradigms for success. We look forward to seeing you in Cambridge, October 16-18, 2007!